Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of ...
In patients with COPD both with or without heart failure, AF episodes rise around the time patients are hospitalized for ...
Medically reviewed by Kashif J. Piracha, MD Medically reviewed by Kashif J. Piracha, MD Acute kidney failure, now known as ...
Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth ...
The surprise finding hints that anti–acid reflux therapy may provide benefit in COPD, possibly by reducing micro-aspirations, ...
The following is a summary of “Clinical Effectiveness and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease ...
Long COVID development may be influenced by severity of the initial COVID-19 illness and pre-existing respiratory conditions, including COPD and OSA.
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...
Krunal Patel, MD, Temple University Hospital, highlights CHEST 2024 data revealing why timing matters with acute pulmonary embolism (PE) intervention.
Exacerbations are recognized to be crucial acute events that are associated with increased hospitalization rates and ...